BiomX Inc - חוב לטווח קצר של החברה PHGE

The expansion of the patient base following the merger with Adaptive Phage and FDA support are impacting operational expenditures for BiomX Inc. (PHGE). This chart from GURU.Markets illustrating current liabilities captures the dynamics of obligations, where the value 0.00 reflects the metric's balance. Stability is maintained through the outsourcing of production to CDMO facilities and management's strategy to develop personalized phage therapies to combat resistant bacteria.

Ensuring the uninterrupted supply of bacteriophages through diversified logistics channels requires stable working capital management. This metric captures the aggregate of liabilities with a maturity of up to one year, allowing investors to assess liquidity risk and the efficiency of financing operating cycles, which makes short-term debt statistics a key indicator of the financial stability of BiomX Inc. (PHGE) in the face of potential cash flow gaps.